Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Non Operating Income (2023 - 2025)

CG Oncology filings provide 3 years of Non Operating Income readings, the most recent being $29.9 million for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 497866.67% to $29.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.1 million, a 150.02% increase, with the full-year FY2025 number at $29.8 million, up 992533.33% from a year prior.
  • Non Operating Income hit $29.9 million in Q4 2025 for CG Oncology, up from -$100000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $29.9 million in Q4 2025 to a low of -$100000.0 in Q3 2025.
  • Median Non Operating Income over the past 3 years was $1.7 million (2023), compared with a mean of $4.8 million.
  • The widest YoY moves for Non Operating Income: up 497866.67% in 2025, down 101.27% in 2025.
  • CG Oncology's Non Operating Income stood at $2.8 million in 2023, then plummeted by 99.79% to $6000.0 in 2024, then surged by 497866.67% to $29.9 million in 2025.
  • The last three reported values for Non Operating Income were $29.9 million (Q4 2025), -$100000.0 (Q3 2025), and $7.3 million (Q2 2025) per Business Quant data.